Azenta (NASDAQ:AZTA) Announces Quarterly Earnings Results, Beats Estimates By $0.17 EPS

Azenta (NASDAQ:AZTA) issued its quarterly earnings data on Tuesday. The company reported $0.28 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.11 by $0.17, FiscalAI reports. The firm had revenue of $167.09 million during the quarter, compared to analysts’ expectations of $160.21 million. Azenta had a positive return on equity of 1.18% and a negative net margin of 20.63%.

Azenta Stock Performance

AZTA stock traded down $0.47 on Tuesday, reaching $40.48. The company had a trading volume of 675,892 shares, compared to its average volume of 938,985. The company’s fifty day moving average is $35.48 and its 200 day moving average is $28.47. The company has a market cap of $1.77 billion, a P/E ratio of -14.67 and a beta of 1.47. Azenta has a 1 year low of $15.93 and a 1 year high of $46.41.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on AZTA shares. Wall Street Zen cut Azenta from a “buy” rating to a “hold” rating in a research report on Sunday, October 18th. Weiss Ratings upgraded shares of Azenta from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, August 26th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $37.00 price objective on shares of Azenta in a research note on Monday, September 14th. Four analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $41.20.

About Azenta

Azenta, Inc. provides products and services for life sciences research and the management of biological samples. Its offerings include automated sample storage systems, laboratory automation equipment, consumables, and software used to track and manage samples. The company also provides genomic services through GENEWIZ, including sequencing and other genetic analysis services for researchers and organizations in the life sciences and pharmaceutical industries. Azenta was formed in 2021 when Brooks Automation separated its life sciences business and adopted the Azenta name.